Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Polyethylene Glycol 4000 · Entresto

Other · developed by Novartis Pharmaceuticals

Approved FDA
1 Registered trials

What is Polyethylene Glycol 4000?

Polyethylene glycol 4000 is an osmotic agent formulated with electrolytes and sodium sulfate that passes through the gastrointestinal tract without net absorption of fluid or electrolytes. It is used in bowel cleansing before colonoscopy and other colorectal and genitourinary tract examinations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Entresto
Drug type
Other
Therapy area
Gastroenterology
Developer
Novartis Pharmaceuticals Corporation
In trials of
RFL
FDA status
Approved as Entresto, NDA207620 · FDA label

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02073552 Phase 4 Colonoscopy Preparation Completed RFL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colonoscopy Preparation

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.